DMD Simcyp - the leader in IVIVE

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on August 19, 2004; DOI: 10.1124/dmd.104.000927


0090-9556/04/3211-1325-1330$20.00
DMD 32:1325-1330, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.000927v1
32/11/1325    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uhing, M. R.
Right arrow Articles by Kimura, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uhing, M. R.
Right arrow Articles by Kimura, R. E.

THE EFFECT OF ANESTHESIA AND SURGERY ON CYP3A ACTIVITY IN RATS

Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall, and Robert E. Kimura

Section of Neonatology, Department of Pediatrics, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois (M.R.U, D.W.A.B, V.A.J.-S., Y.C., R.E.K); Department of Industrial & Physical Pharmacy, School of Pharmacy, Purdue University, West Lafayette, Indiana (R.E.G.); and Division of Clinical Pharmacology, Department of Medicine, Indiana University, Indianapolis, Indiana (R.E.G., S.D.H.)

The purpose of this investigation was to examine the effects of surgery and anesthesia on in vivo CYP3A activity and portal venous blood flow. Midazolam, a CYP3A probe for both rats and humans, was administered orally (2.7 mg), intravenously (0.57 mg), or via the portal vein (0.57 mg) to rats 4 h after anesthesia with ketamine/xylazine and surgery for placement of indwelling vascular and duodenal catheters and 3 days after surgery (chronic). The systemic clearance of midazolam was 51 ± 4 ml/min/kg in the chronic animals, and this was significantly decreased (29 ± 1 ml/min/kg, P = 0.024) in acute rats studied 4 to 6 h after anesthesia and surgery. The hepatic availability (FH), directly determined from the aortic and hepatic venous concentration gradient, was significantly higher in the acute animals (0.57 ± 0.05) compared with the chronic animals (0.33 ± 0.07, P = 0.001). Hepatic availability was determined using a classical approach in which FH was calculated from the area under the plasma concentration versus time curve ratio after portal venous or intravenous administration. FH was higher in the acute rats (0.48) compared with the chronic animals (0.27 ± 0.03). Portal venous blood flow was significantly lower in the acute animals (5.0 ± 0.4 ml/min/100 g body weight) compared with the chronic animals (9.1 ± 0.9 ml/min/100 g body weight, P = 0.015). The effect of surgery and anesthesia was confirmed using the indicator dye dilution method after infusion of [14C]polyethylene glycol 4000 into the superior mesenteric artery. Our data suggest that anesthesia and surgery decreases both hepatic CYP3A activity and hepatic blood flow in rats. Studies performed in rats within 3 days of surgery and anesthesia are conducted under nonphysiologic conditions and therefore provide inaccurate assessment of drug disposition, in particular, clearance and bioavailability.


Address correspondence to: Dr. Raymond E. Galinsky, Division of Clinical Pharmacology, W-7123, Wishard Memorial Hospital, 1001 West 10th Street, Indianapolis, IN 46202. E-mail: rgalinsk{at}iupui.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
C. A. Evans, L. J. Jolivette, R. Nagilla, and K. W. Ward
EXTRAPOLATION OF PRECLINICAL PHARMACOKINETICS AND MOLECULAR FEATURE ANALYSIS OF "DISCOVERY-LIKE" MOLECULES TO PREDICT HUMAN PHARMACOKINETICS
Drug Metab. Dispos., July 1, 2006; 34(7): 1255 - 1265.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.